|  |  | Molecular Subtyping |  |  | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
 | All |  |  |  |  |  |  | Five subtypes | Four subtypes | P value between five subtypes *,†| P value between four subtypes **,†| |||||
Variables | Â | Â | IHC-Luminal A | IHC-Luminal B | IHC-HER2 | IHC-BLBC | IHC-QNBC/5NP | IHC-TNBC | Â | Â | ||||||
 | N = 951 | N = 486 51.1% | N = 123 12.9% | N = 113 11.9% | N = 139 14.6% | N = 90 9.5% | N = 229 24.1% |  |  | |||||||
 | No. | (%) | No. | (%) | No. | (%) | No. | (%) | No. | (%) | No. | (%) | No. | (%) |  |  |
Age Group (years) | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | < 0.001 | < 0.001 |
   > 50 | 590 | 62.0 | 297 | 61.1 | 87 | 70.7 | 51 | 45.1 | 97 | 69.8 | 58 | 64.4 | 155 | 67.7 |  |  |
   ≥ 50 | 361 | 38.0 | 189 | 38.9 | 36 | 29.3 | 62 | 54.9 | 42 | 30.2 | 32 | 35.6 | 74 | 32.3 |  |  |
Family history of breast cancer | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | 0.006 | 0.086 |
   No | 916 | 96.3 | 470 | 96.7 | 121 | 98.4 | 111 | 98.2 | 126 | 90.6 | 88 | 97.8 | 214 | 93.4 |  |  |
   Yes | 35 | 3.7 | 16 | 3.3 | 2 | 1.6 | 2 | 1.8 | 13 | 9.4 | 2 | 2.2 | 15 | 6.6 |  |  |
Tumor Size | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | 0.014 | 0.006 |
   ≤ 2 cm | 392 | 41.2 | 228 | 46.9 | 39 | 31.7 | 35 | 31.0 | 52 | 37.4 | 38 | 42.2 | 90 | 39.3 |  |  |
   2-5 cm | 493 | 51.8 | 231 | 47.5 | 75 | 61.0 | 64 | 56.6 | 76 | 54.7 | 47 | 52.2 | 123 | 53.7 |  |  |
   > 5 cm | 66 | 6.9 | 27 | 5.6 | 9 | 7.3 | 14 | 12.4 | 11 | 7.9 | 5 | 5.6 | 16 | 7.0 |  |  |
N Staging | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | 0.178 | 0.014 |
   N0 | 498 | 52.4 | 246 | 50.6 | 52 | 42.3 | 63 | 55.8 | 89 | 64.0 | 48 | 53.3 | 137 | 59.8 |  |  |
   N1 | 247 | 25.9 | 131 | 27.0 | 40 | 32.5 | 22 | 19.5 | 31 | 22.3 | 23 | 25.6 | 54 | 23.6 |  |  |
   N2 | 118 | 12.4 | 64 | 13.2 | 19 | 15.4 | 13 | 11.5 | 12 | 8.6 | 10 | 11.1 | 22 | 9.6 |  |  |
   N3 | 88 | 9.2 | 45 | 9.3 | 12 | 9.8 | 15 | 13.3 | 7 | 5.0 | 9 | 10.0 | 16 | 7.0 |  |  |
AJCC stage | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | 0.014 | 0.008 |
   I | 254 | 26.7 | 148 | 30.5 | 19 | 15.4 | 22 | 19.5 | 38 | 27.3 | 27 | 30.0 | 65 | 28.4 |  |  |
   II | 467 | 49.1 | 221 | 45.5 | 69 | 56.1 | 57 | 5.04 | 78 | 56.1 | 42 | 46.7 | 120 | 52.4 |  |  |
   III | 230 | 24.2 | 117 | 24.1 | 35 | 28.5 | 34 | 30.1 | 23 | 16.5 | 21 | 23.3 | 44 | 19.2 |  |  |
LN involvement | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | 0.016 | 0.020 |
   Negative | 498 | 52.4 | 246 | 50.6 | 52 | 42.3 | 63 | 55.8 | 89 | 64.0 | 48 | 53.3 | 137 | 59.8 |  |  |
   Positive | 453 | 47.6 | 240 | 49.4 | 71 | 57.7 | 50 | 44.2 | 50 | 36.0 | 42 | 46.7 | 92 | 40.2 |  |  |
Nuclear Grade | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | < 0.001 | < 0.001 |
   Low | 92 | 9.7 | 67 | 13.8 | 5 | 4.1 | 3 | 2.7 | 9 | 6.5 | 8 | 8.8 | 17 | 7.4 |  |  |
   Intermediate | 486 | 51.1 | 308 | 63.4 | 65 | 52.8 | 40 | 35.4 | 26 | 18.7 | 47 | 52.2 | 73 | 31.9 |  |  |
   High | 373 | 39.2 | 111 | 22.8 | 53 | 43.1 | 70 | 61.9 | 104 | 74.8 | 35 | 38.9 | 139 | 60.7 |  |  |
Histological Grade | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | < 0.001 | < 0.001 |
   Well | 100 | 10.5 | 63 | 13.0 | 10 | 8.1 | 11 | 9.7 | 8 | 5.8 | 8 | 8.9 | 16 | 7.0 |  |  |
   Moderate | 597 | 62.8 | 334 | 68.7 | 76 | 61.8 | 65 | 57.5 | 71 | 51.1 | 51 | 56.7 | 122 | 53.3 |  |  |
   Poor | 254 | 26.7 | 89 | 18.3 | 37 | 30.1 | 37 | 32.7 | 60 | 43.2 | 31 | 34.4 | 91 | 39.7 |  |  |
Estrogen Receptor (ER) | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | < 0.001 | < 0.001 |
   Negative | 364 | 38.3 | 11 | 2.3 | 11 | 8.9 | 113 | 100.0 | 139 | 100.0 | 90 | 100.0 | 229 | 100.0 |  |  |
   Positive | 587 | 61.7 | 475 | 97.7 | 112 | 91.1 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |  |  |
Progesterone Receptor (PR) | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | < 0.001 | < 0.001 |
   Negative | 522 | 54.9 | 143 | 29.4 | 37 | 30.1 | 113 | 100.0 | 139 | 100.0 | 90 | 100.0 | 229 | 100.0 |  |  |
   Positive | 429 | 45.1 | 343 | 70.6 | 86 | 69.9 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |  |  |
HER2 | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
   Negative | 715 | 75.2 | 486 | 100.0 | 0 | 0.0 | 0 | 0.0 | 139 | 100.0 | 90 | 100.0 | 229 | 100.0 |  |  |
   Positive | 236 | 24.8 | 0 | 0.0 | 123 | 100.0 | 113 | 100.0 | 0 | 0.0 | 0 | 0.0 | 0 | 0.0 |  |  |
CK 5/6 | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
   Negative | 820 | 86.2 | 474 | 97.7 | 123 | 100.0 | 103 | 91.2 | 30 | 21.6 | 90 | 100.0 | 120 | 52.4 |  |  |
   Positive | 131 | 13.8 | 12 | 2.5 | 0 | 0.0 | 10 | 8.8 | 109 | 78.4 | 0 | 0.0 | 109 | 47.6 |  |  |
EGFR | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
   Negative | 821 | 86.3 | 471 | 96.9 | 119 | 96.7 | 92 | 81.4 | 49 | 35.3 | 90 | 100.0 | 139 | 60.7 |  |  |
   Positive | 130 | 13.7 | 15 | 3.1 | 4 | 3.3 | 21 | 18.6 | 90 | 64.7 | 0 | 0.0 | 90 | 39.3 |  |  |
Histological type | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
   Invasive ductal carcinoma | 872 | 91.6 | 438 | 90.1 | 122 | 99.2 | 106 | 93.8 | 125 | 89.9 | 81 | 90.0 | 206 | 90.0 |  |  |
   Invasive lobular carcinoma | 26 | 2.7 | 22 | 4.5 |  |  |  |  |  |  | 4 | 4.4 | 4 | 1.7 |  |  |
   Mucinous carcinoma | 13 | 1.4 | 10 | 2.1 |  |  | 2 | 1.8 |  |  | 1 | 1.1 | 1 | 0.4 |  |  |
   Invasive papillary carcinoma | 8 | 0.8 | 5 | 1.0 | 1 | 0.8 |  |  | 2 | 1.4 |  |  | 2 | 0.9 |  |  |
   Medullary carcinoma | 10 | 1.1 | 1 | 0.2 |  |  | 1 | 0.9 | 8 | 5.8 |  |  | 8 | 3.5 |  |  |
   Metaplastic carcinoma | 6 | 0.6 | 1 | 0.2 |  |  |  |  | 3 | 2.2 | 2 | 2.2 | 5 | 2.2 |  |  |
   Others | 18 | 1.6 | 9 | 1.9 |  |  | 3 | 2.7 |  |  |  |  |  |  |  |  |
Operation | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
   BCS | 359 | 37.7 | 200 | 41.2 | 40 | 32.5 | 30 | 26.5 | 58 | 41.7 | 31 | 34.4 | 89 | 38.9 | 0.048 | 0.038 |
   Mastectomy | 592 | 62.3 | 286 | 58.8 | 83 | 67.5 | 83 | 73.5 | 81 | 58.3 | 59 | 65.6 | 140 | 61.1 |  |  |
Adjuvant chemotherapy | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
   Not done | 155 | 16.3 | 95 | 19.5 | 20 | 16.3 | 22 | 19.5 | 10 | 7.2 | 8 | 8.9 | 18 | 7.9 | 0.004 | 0.002 |
   Done | 796 | 83.7 | 391 | 80.5 | 103 | 83.7 | 91 | 80.5 | 129 | 92.8 | 82 | 91.1 | 211 | 92.1 |  |  |
Anthracycline | 292 | 36.7 | 156 | 39.9 | 40 | 38.8 | 33 | 36.3 | 34 | 11.6 | 29 | 35.4 | 63 | 29.9 | 0.101 | 0.114 |
CMF | 491 | 61.7 | 229 | 58.6 | 61 | 59.2 | 58 | 63.7 | 92 | 71.3 | 51 | 62.2 | 143 | 67.8 | Â | Â |
Others | 13 | 1.6 | 6 | 1.5 | 2 | 1.9 | 0 | 0 | 3 | 2.3 | 2 | 2.4 | 5 | 2.4 | Â | Â |
Radiation therapy | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â | Â |
   Not done | 503 | 52.9 | 250 | 51.4 | 73 | 59.3 | 63 | 55.8 | 69 | 49.6 | 48 | 53.3 | 117 | 51.1 | 1.0 | 1.0 |
   Done | 448 | 47.1 | 236 | 48.6 | 50 | 40.7 | 50 | 44.2 | 70 | 50.4 | 42 | 46.7 | 112 | 48.9 |  |  |